Core Laboratories Inc. /DE/ Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q3 FY202510-Q · 2025-09-30 | $134.5M | — | $14.2M | — | $20.9M | $0.30 |
| Q2 FY202510-Q · 2025-06-30 | $0 | — | $10.6M | — | -$60.0K | $0.22 |
| Q1 FY202510-Q · 2025-03-31 | $68.0K | — | -$154.0K | — | $2.3M | $0.00 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q3 FY202510-Q | $591.4M | — | $25.6M | $271.3M |
| Q2 FY202510-Q | $133.0M | — | $31.2M | $261.3M |
| Q1 FY202510-Q | $118.5M | — | $22.1M | $253.4M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q3 FY202510-Q | $20.9M | $14.2M | — | 46,086,944 |
| Q2 FY202510-Q | -$60.0K | $10.6M | — | 46,536,790 |
| Q1 FY202510-Q | $2.3M | -$154.0K | — | 46,702,192 |
Filings
(4)Methodology
Every figure on this page is pulled directly from Core Laboratories Inc. /DE/'s own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].